ELOX ▲ +5.0% - Eloxx Pharmaceuticals, Inc.
$ELOX - Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
20-OCT-2026 09:34 AM ET
Share this post
More filings for $ELOX
ELOX ▼ -4.3% - Eloxx Pharmaceuticals, Inc.Oct 19, 2026ELOX - Eloxx Pharmaceuticals, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$ELOX SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $ELOX filing history →💬 Comments
Loading comments…
Leave a comment